VivoSeq
Other

Subcutaneous Fat

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Subcutaneous Fat is an early-stage landscape with 0 programs across 2 companies. The most active players are Caliway Biopharmaceuticals Co., Ltd., Kythera Biopharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Caliway Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalK

Kythera Biopharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed11 · 100%

Clinical Trials

Trial Activity

11 trials

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 1·NCT04699669·40 enrolled
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04698642·43 enrolled
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Completed·PPennington Biomedical Research Center·N/A·NCT01748994·63 enrolled
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05736107·107 enrolled
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Completed·KKythera Biopharmaceuticals·Phase 3·NCT01542034·506 enrolled
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Completed·KKythera Biopharmaceuticals·Phase 3·NCT01546142·516 enrolled
"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
Completed·PPennington Biomedical Research Center·Phase 2·NCT00377975·96 enrolled
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04897412·75 enrolled
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Completed·KKythera Biopharmaceuticals·Phase 3·NCT01426373·165 enrolled
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04575467·25 enrolled
Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age
Completed·KKythera Biopharmaceuticals·Phase 3·NCT02123134·55 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)